Pulmonary hypertension
MONDO:0005149Increased pressure within the pulmonary circulation due to lung or heart disorder.
375 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Implanted sensors could personalize PAH drug plans
Disease control OngoingThis study tests whether implanted monitors can quickly show if a new PAH drug is working. About 40 adults with stable PAH will try two different approved drug plans while their heart and lung function are tracked. The goal is to see if this approach can help doctors choose the b…
Phase: PHASE4 • Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could this pill help kids with rare lung disease?
Disease control OngoingThis study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New inhaled drug shows promise for rare lung disease
Disease control OngoingThis study looks at the long-term safety of an inhaled drug called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition. It includes 74 patients who already completed a previous GB002 study. Researchers will track side effects and measure how far …
Phase: PHASE2 • Sponsor: Gossamer Bio USA, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New pill could help heart failure patients breathe easier and walk farther
Disease control OngoingThis study tests an oral medication called levosimendan in people who have both pulmonary hypertension (high blood pressure in the lungs) and a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug helps them walk farther in 6 minutes c…
Phase: PHASE3 • Sponsor: Tenax Therapeutics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Heart-Lung hope: new drug sotatercept tested for tough hypertension
Disease control OngoingThis study looks at the long-term safety of a drug called sotatercept for people with a specific type of pulmonary hypertension caused by heart failure with preserved ejection fraction. About 130 people who completed a prior study will receive sotatercept injections and be monito…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Zapping lung nerves could ease heart Failure-Related high blood pressure
Disease control OngoingThis trial tests a procedure called pulmonary arterial denervation (PADN) for people with heart failure who also have high blood pressure in the lungs. A special catheter delivers radiofrequency energy to nerves in the pulmonary artery, which may help lower pressure and improve h…
Phase: PHASE3 • Sponsor: Pulnovo Medical (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New inhaled powder shows promise for Long-Term PAH control
Disease control OngoingThis study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to ease lung pressure in heart failure patients
Disease control OngoingThis study tests an experimental drug called TX000045 in 180 adults with pulmonary hypertension (high blood pressure in the lungs) caused by a type of heart failure where the heart pumps normally but doesn't relax properly. Participants will receive either the drug or a placebo f…
Phase: PHASE2 • Sponsor: Tectonic Therapeutic • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a new dose of selexipag help kids with rare lung disease?
Disease control OngoingThis study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Higher dose of PAH drug may keep patients out of hospital longer
Disease control OngoingThis phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a Heart-Lung drug help kids with pulmonary hypertension?
Disease control OngoingThis study tests a drug called riociguat in children aged 6 to 18 who have pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. The goal is to see if the drug is safe and how the body processes it at differen…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Tiny heart implant aims to ease strain in rare lung disease
Disease control OngoingThis early study tests a small, permanent device called the V-Wave Interatrial Shunt in 9 people with severe pulmonary arterial hypertension (PAH). The device is placed in the heart during a minimally invasive procedure to create a small opening between the upper chambers, which …
Phase: NA • Sponsor: V-Wave Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug candidate targets Hard-to-Treat lung condition
Disease control OngoingThis early-stage study by Pfizer tests a new drug called PF-07868489. First, it will be given to healthy volunteers to check safety and how the body processes it. Then, people with pulmonary arterial hypertension (PAH) will receive repeated doses over 24 weeks to see if it helps …
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Ultrasound zaps lung nerves to ease heart failure symptoms
Disease control ENROLLING_BY_INVITATIONThis early study is testing a device that uses ultrasound to ablate (calm) nerves in the pulmonary artery. The goal is to see if this procedure can improve quality of life for 50 people with heart failure and a specific type of pulmonary hypertension (Group 2). Participants will …
Phase: NA • Sponsor: Gradient Denervation Technologies • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart failure drug study pulled before it even started
Disease control TerminatedThis study was designed to test the safety and tolerability of a new drug called JK07 in people with heart failure and a specific type of high blood pressure in the lungs. It planned to enroll about 20 to 30 adults aged 18 to 85. However, the study was withdrawn before any partic…
Phase: PHASE2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New inhaled drug aims to help COPD patients walk farther
Disease control OngoingThis study tests an inhaled drug called frespaciguat (MK-5475) in 129 adults who have high blood pressure in their lungs caused by COPD. The main goal is to see if the drug helps people walk farther in 6 minutes after 24 weeks compared to a placebo. Participants take one daily in…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug oxacom® shows promise for treating rare lung condition
Disease control OngoingThis study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal…
Phase: PHASE2, PHASE3 • Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New registry follows PAH patients on orenitram in Real-World settings
Disease control OngoingThis study is a patient registry that follows 300 adults with pulmonary arterial hypertension (PAH) who are starting or recently started Orenitram. Researchers will track how well patients tolerate the drug and how it affects their daily function and symptoms over 78 weeks. The g…
Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New inhaled therapy aims to ease lung blood pressure
Disease control OngoingThis study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…
Phase: PHASE3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New inhaled drug aims to help patients with lung scarring and high blood pressure
Disease control TerminatedThis phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug tame rare bleeding Disorder's heart complications?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New inhaled drug aims to ease lung scarring and heart strain
Disease control OngoingThis Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…
Phase: PHASE2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for PAH patients: Long-Term drug safety trial opens
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug remains s…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Implantable pump for PAH drug passes safety check
Disease control OngoingThis study tests an implanted catheter and pump system that delivers Remodulin, a drug for pulmonary arterial hypertension (PAH), directly into the bloodstream. The goal is to see if this device is safe for long-term use. The trial includes 64 patients who already use the system.…
Phase: NA • Sponsor: Medtronic Cardiac Rhythm and Heart Failure • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for PAH: rapid drug therapy aims to reverse heart damage
Disease control OngoingThis study tests whether quickly starting and increasing a medication called treprostinil can lower blood pressure in the lungs and improve the heart's pumping ability in people with pulmonary arterial hypertension (PAH). The trial involves 52 adults with PAH and will measure cha…
Phase: PHASE4 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for PAH patients: sotatercept safety trial expands
Disease control OngoingThis study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Participants from an earlier study can join and receive weight-based doses every 3 weeks. The main goal is to see if the medicine is safe and well-tole…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Diet and exercise may ease rare lung disease
Disease control OngoingThis study tests whether a 12-week program of exercise and diet counseling can improve insulin sensitivity and heart function in people with pulmonary arterial hypertension (PAH). The 34 participants have stable PAH and are already on standard medications. The goal is to see if l…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Timing of cord clamp could save lungs in rare birth defect
Disease control OngoingThis study tests whether waiting to clamp the umbilical cord until after the baby's lungs have filled with air can reduce dangerous lung blood pressure (pulmonary hypertension) in newborns with congenital diaphragmatic hernia (CDH). About 140 infants with left-sided CDH will be r…
Phase: NA • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 26, 2026 17:00 UTC
-
A Needle-Free heart check? MRI may replace invasive catheterization
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether a new MRI technique, called 5D flow, can measure blood flow and pressure in the heart as accurately as the standard invasive procedure, right-left heart catheterization. People with congenital heart conditions who already need a catheterization will also …
Phase: NA • Sponsor: Tobias Rutz • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Artificial intelligence may detect Children's heart disease from a routine ECG
Diagnosis TerminatedThis trial is developing an artificial intelligence system that reads electrocardiograms (ECGs) to detect congenital heart disease in children. Researchers are collecting ECG data from thousands of children, including those with common and rare heart defects, to train a deep-lear…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New heart scan method could catch hidden lung pressure earlier
Diagnosis OngoingThis study looks at whether a new computer program called IMPULSE can better detect pulmonary hypertension (high blood pressure in the lungs) using standard heart ultrasound. About 200 adults with unexplained breathlessness or risk factors will be checked. The goal is to see if t…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New baby blood pressure monitor could save tiny lives
Diagnosis ENROLLING_BY_INVITATIONThis study tests a new, gentle device called Boppli that continuously measures blood pressure in newborn babies in the NICU. Researchers will compare it to the standard blood pressure cuff to see if it works better at finding high blood pressure. The study includes 30 infants at …
Phase: NA • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Text message workouts could ease strain on hearts of PAH patients
Symptom relief OngoingThis study tests whether a home rehabilitation program using daily text or email messages with simple exercises can reduce the number of heartbeats needed during a 6-minute walk in people with pulmonary arterial hypertension (PAH). Researchers will enroll 55 adults with PAH and c…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Can exercise ease the burden of pulmonary hypertension? new study investigates
Symptom relief OngoingThis study tests whether whole-body aerobic training (like brisk walking) or isolated leg training (with weights) better improves symptoms and quality of life in people with pulmonary arterial hypertension (PAH). About 45 participants with PAH will be assigned to one of the two e…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Exercise as medicine: could cardiac rehab ease a double Heart-Lung condition?
Symptom relief TerminatedThis study tests whether 10 weeks of supervised exercise training can improve heart function, oxygen use, and quality of life in people with heart failure and pulmonary hypertension. Forty participants will do three sessions per week at a cardiac rehab clinic. The goal is to see …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Virtual reality workouts tested for rare lung condition
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether exercise delivered through immersive virtual reality can improve physical performance, muscle strength, fatigue, and quality of life in 32 adults with idiopathic pulmonary arterial hypertension. Participants will do virtual reality exercises and be measur…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Simple breathing workout may ease strain on heart in lung condition
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether six weeks of daily breathing exercises against resistance can improve heart and lung function in people with pulmonary hypertension. Four participants will do 30 resisted breaths per day, five days a week. Researchers will measure changes in heart pressur…
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Scoliosis's hidden toll: can we predict lung and heart risks?
Knowledge-focused OngoingThis study looks back at 10 years of medical records from a scoliosis referral center to see how frequently adults with scoliosis who had surgery also develop restrictive breathing problems or signs of pulmonary hypertension on echocardiography. By analyzing data from 174 patient…
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a protein on blood vessel cells be key to treating a rare heart condition?
Knowledge-focused ENROLLING_BY_INVITATIONThis study investigates whether a drug called XBD173, which targets a protein (TSPO) on blood vessel lining cells, can help understand how these cells contribute to pulmonary artery hypertension (PAH). PAH is a rare condition where narrowed lung blood vessels strain the heart. Si…
Phase: PHASE1 • Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Short step test may simplify fitness checks for lung patients
Knowledge-focused OngoingThis study looks at whether a 2-minute step test can accurately measure exercise ability in people with pulmonary hypertension, compared to the standard 6-minute walk test. Researchers will enroll 35 adults with the condition and measure oxygen use, heart rate, and breathlessness…
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Lung vessel test for heart defect patients pulled before starting
Knowledge-focused TerminatedThis study was designed to see if a test using acetylcholine could predict whether people with congenital heart disease and high blood pressure in the lungs would develop worsening high blood pressure after surgery to close a heart shunt. The test would have measured how well the…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Lung blood tests may guide smarter treatment for pulmonary hypertension
Knowledge-focused OngoingThis study looks at whether adding special blood tests (biomarkers) to the usual heart-lung exam can help doctors pick the right therapy for people with pulmonary hypertension. About 100 adults undergoing a routine heart catheterization will have extra blood samples taken from th…
Sponsor: Vanderbilt University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lung condition may affect brain function, new study hints
Knowledge-focused OngoingThis study looks at whether people with pulmonary arterial hypertension (PAH) have changes in thinking skills like memory and attention. Researchers will compare 30 PAH patients to healthy volunteers using computer-based tests. The goal is to better understand how PAH might affec…
Sponsor: Alessandra Gorini • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Study to test finger cuff for heart monitoring in lung disease patients withdrawn before starting
Knowledge-focused TerminatedThis study was designed to see if a non-invasive finger cuff device could accurately measure how well the heart pumps blood in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). The goal was to replace the usual invasive ri…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Heart valve study pulled before it began
Knowledge-focused TerminatedThis study was designed to find early warning signs of high blood pressure in the lungs after mitral valve surgery. Researchers planned to use blood tests and heart imaging to detect problems that could be deadly if missed. The study was withdrawn before enrolling any participant…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Scientists investigate link between blood fats and sickle cell crises
Knowledge-focused OngoingThis study looks at how different types of fats in the blood (like cholesterol) are linked to complications in adults with sickle cell disease. Researchers will follow 116 participants from the French Caribbean islands to track their fat levels over time and during acute events l…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de la Guadeloupe • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may predict lung transplant need in PH patients
Knowledge-focused OngoingThis study is collecting blood samples from 550 adults with different types of pulmonary hypertension to measure two proteins, Activin-A and FSTL3. Researchers want to see if these proteins can predict who will need a lung transplant or die within two years. The goal is to find a…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Massive study aims to redefine Lung-Heart disease
Knowledge-focused OngoingThis study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve fu…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Can urine tests predict kidney trouble in lung patients?
Knowledge-focused OngoingThis observational study follows 350 adults with pulmonary hypertension to see if certain biomarkers in urine and blood are linked to worsening kidney function. Participants undergo standard tests but receive no experimental treatment. The goal is to better understand how kidney …
Sponsor: University of Giessen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Fitness trackers vs. walking tests: which better predicts lung disease outcomes?
Knowledge-focused OngoingThis study looks at whether wearing an activity tracker (like a Fitbit) can better predict how people with pulmonary hypertension will do over 12 weeks compared to the standard 6-minute walk test. About 230 participants will wear the tracker and report how they feel. The goal is …
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC